This study evaluated the postprandial (PP) response to an oral fat load in 28 male patients
with type 2 diabetes (mean HbA1c of 5.1%), all receiving metformin and performing physical …

Aims: To determine the effects of micronised fenofibrate on lipids and low density lipoprotein
(LDL) subfraction in well-controlled diabetic subjects with mild elevations in cholesterol …

Background To assess the short‐term effects of a micronised formulation of fenofibrate on
lipids, lipoproteins and their composition, reflecting an atherogenic lipoprotein phenotype …

Background: The metabolic syndrome (MS) is often accompanied by atherogenic
dyslipidemia, which is characterized by elevated triglycerides (TG), reduced high‐density …

Background Type 2 diabetes is associated with early development of endothelial
dysfunction. Patients present with typical dyslipidemia (predominantly high levels of …

OBJECTIVE—The aim of this study was to determine the effects of fenofibrate (160 mg/day)
on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in …

The aim of this study was to evaluate the levels of lipid and extralipid parameters in patients
with atherogenic dyslipidemia. We investigated the lipid-lowering therapeutic efficacy of …

Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the
activation of peroxisome proliferator-activated receptor-α. Fenofibrate also has a number of …

A randomized, double-blind, placebo-controlled study was undertaken in 20
hypertriglyceridemic men [plasma triglyceride (TG),> 2.3 mM] with low levels (< 0.9 mM) of …

Background: Multiple trials have demonstrated the efficacy of fenofibrate for the
management of dyslipidemia. Real-world evidence may provide important insights into the …